Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02910518
Other study ID # BEQ13941
Secondary ID 2016-001498-34U1
Status Completed
Phase Phase 1
First received
Last updated
Start date February 17, 2017
Est. completion date May 3, 2017

Study information

Verified date April 2022
Source Sanofi
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Primary Objective: To demonstrate bioequivalence between insulin glulisine given as 300 Units/mL test formulation and insulin glulisine 100 Units/mL reference formulation after a single subcutaneous (SC) dose. Secondary Objectives: - To assess the pharmacodynamic (PD) profiles and further pharmacokinetic (PK) characteristics of insulin glulisine U300 in comparison to insulin glulisine U100 after a single SC dose. - To assess safety and tolerability of the test and the reference formulation of insulin glulisine.


Description:

The study duration per patient will be 18 to 62 days and will consist of a 4 to 28 days of screening period, a treatment period of 2 days, a washout between dosing occasions of 5-18 days, and follow up visit 7-14 days after last dosing.


Recruitment information / eligibility

Status Completed
Enrollment 44
Est. completion date May 3, 2017
Est. primary completion date May 3, 2017
Accepts healthy volunteers No
Gender All
Age group 18 Years to 64 Years
Eligibility Inclusion criteria : - Male or female subjects with type 1 diabetes mellitus (T1DM) for more than 1 year. - Total insulin dose of <1.2 U/kg/day. - Fasting negative serum C-peptide (<0.30 nmol/L). - Glycohemoglobin at screening (HbA1c) =9%. - Subjects with anti-insulin antibody titer at screening =30.0 kU/L. - Stable insulin regimen for at least 2 months prior to study. - Normal findings in medical history and physical examination (cardiovascular system, chest and lungs, thyroid, abdomen, nervous system, skin and mucosae, and musculoskeletal system), vital signs, electrocardiogram (ECG), and safety laboratory. Exclusion criteria: - Any history or presence of clinically relevant cardiovascular, pulmonary, gastrointestinal, hepatic, renal, metabolic (apart from T1DM), hematological, neurological, psychiatric, systemic (affecting the body as a whole), ocular, gynecologic (if female), or infectious disease; any acute infectious disease or signs of acute illness or any history or presence of heparin induced thrombocytopenia Type II (HIT-type II). - Severe hypoglycemia resulting in coma/seizures or requiring assistance of another person, and/or hospitalization for diabetic ketoacidosis in the last 6 months before screening visit. - Frequent severe headaches and/or migraine, recurrent nausea and/or vomiting (more than twice a month). - Symptomatic hypotension (whatever the decrease in blood pressure), or asymptomatic postural hypotension defined by a decrease in systolic blood pressure equal to or greater than 20 mmHg within three minutes when changing from the supine to the standing position. - Presence or history of drug hypersensitivity, or allergic disease diagnosed and treated by a physician. - Likelihood of requiring treatment during the study period with drugs not permitted by the clinical study protocol. - Any medication (including medicine containing St John's Wort) within 14 days before inclusion (for systemic glucocorticoids within 3 months) or within 5 times the elimination half-life or PD half-life of the medication, with the exception of insulin, stable treatment (at least 2 months) with thyroid hormones, lipid-lowering and antihypertensive drugs and if female with the exception of hormonal contraception or menopausal hormone replacement therapy. - Positive reaction to any of the following tests: hepatitis B surface (HBs Ag) antigen, anti hepatitis C virus (anti-HCV) antibodies, anti-human immunodeficiency virus 1 and 2 antibodies (anti-HIV1 and anti HIV2 Ab). The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Study Design


Intervention

Drug:
Insulin glulisine (U300)
Pharmaceutical form: solution Route of administration: subcutaneous
Insulin glulisine
Pharmaceutical form: solution Route of administration: subcutaneous
Insulin aspart
Pharmaceutical form: solution Route of administration: intravenous/subcutaneous
NPH insulin
Pharmaceutical form: solution Route of administration: subcutaneous
Glucagon
Pharmaceutical form: Powder and solvent for solution for injection Route of administration: subcutaneous
Glucose
Pharmaceutical form: solution Route of administration: intravenous
Heparin
Pharmaceutical form: solution Route of administration: intravenous

Locations

Country Name City State
Germany Investigational Site Number 276001 Neuss

Sponsors (1)

Lead Sponsor Collaborator
Sanofi

Country where clinical trial is conducted

Germany, 

Outcome

Type Measure Description Time frame Safety issue
Primary Assessment of PK parameter: maximum observed insulin concentration 10 hours
Primary Assessment of PK parameter: area under the concentration time curve 10 hours
Secondary Assessment of PK parameter: time to reach Cmax (INS-tmax) 10 hours
Secondary Assessment of PK parameter: terminal half-life (INS-t1/2z) 10 hours
Secondary Assessment of PD parameter: area under the body weight standardized glucose infusion rate (GIR) versus time curve from 0 to 10 hours (GIR-AUC0-10) 10 hours
Secondary Assessment of PD parameter: maximum smoothed body weight standardized GIR (GIRmax) 10 hours
Secondary Assessment of PD parameter: time to GIRmax (GIR-tmax) 10 hours
Secondary Duration of blood glucose control under clamp conditions - time 10 hours
Secondary Number of patients with treatment emergent adverse events 9 weeks
See also
  Status Clinical Trial Phase
Completed NCT03623113 - The Dietary Education Trial in Carbohydrate Counting (DIET-CARB Study in Type 1 Diabetes N/A
Withdrawn NCT03396484 - Methyldopa for Reduction of DQ8 Antigen Presentation in At-Risk Subjects for Type 1 Diabetes Phase 2
Completed NCT03117998 - Multiple Dose Study to Evaluate the Efficacy, Safety and Pharmacodynamics of REMD-477 in Subjects With Type 1 Diabetes Mellitus Phase 2
Recruiting NCT03369821 - EXtremely Early-onset Type 1 Diabetes EXtremely Early-onset Type 1 Diabetes (A Musketeers' Memorandum Study)
Completed NCT03202732 - DiabetesFlex - Patient Involvement and Patient-reported Outcome Measures in Type 1 Diabetes N/A
Completed NCT03704818 - Dapagliflozin Effects on Hypoglycemia Phase 1
Recruiting NCT03864991 - Lifestyle Changes and Glycemic Control in T1D N/A
Completed NCT03725657 - Correlation Between Exercise and Insulin Dose in a Camp for Pediatric Type 1 Patients
Completed NCT02985866 - The International Diabetes Closed Loop (iDCL) Trial: Protocol 1 N/A
Completed NCT03003806 - Evaluation of the Dreamed Advisor Pro for Automated Insulin Pump Setting Adjustments in Children and Adolescents With Type 1 Diabetes- The Advice4U Pro Study N/A
Withdrawn NCT04147637 - FreeStyle Libre Plus Bluetooth Transmitter Adjunct: Can This Improve Glucose Accuracy and Reduce Burden of Hypoglycaemia N/A
Completed NCT03970889 - Real-time Reminders To Decrease Late or Missed Meal Boluses N/A
Recruiting NCT04589325 - Ixekizumab Diabetes Intervention Trial (I-DIT) Phase 2
Completed NCT03367390 - A Study of an Automated Insulin Delivery System in Participants With Type 1 Diabetes Mellitus (T1DM) Phase 1
Completed NCT03738852 - Mechanisms for Restoration of Hypoglycemia Awareness Early Phase 1
Completed NCT03406585 - Wharton´s Jelly Derived Mesenchymal Stromal Cell Treatment of Adult Patients Diagnosed With Type I Diabetes Phase 1/Phase 2
Completed NCT03859856 - Ovarian Reserve in Diabetes Mellitus
Withdrawn NCT04102202 - BOL-DP-o-05 as an Add-On Treatment of Subjects With Newly Diagnosed Type 1 Diabetes Mellitus Phase 1/Phase 2
Terminated NCT03353792 - Using an Artificial Pancreas System in Older Adult Type 1 Diabetes Mellitus Patients N/A
Recruiting NCT03811470 - China Diabetes Registry by Metabolic Management Center